Ispecimen INC

iSpecimen Inc. announced the completion of Milestone 3 in its digital transformation program, making a $700,000 payment for enhanced marketplace features and broader rollout.

iSpecimen Inc. has been notified by Nasdaq that it fails to meet the minimum stockholders' equity requirement for continued listing.

iSpecimen Inc. shareholders approved the election of a director, the appointment of auditors, and a new stock incentive plan.

iSpecimen Inc. has secured $2.5 million in gross proceeds through a private placement of common stock and pre-funded warrants.

iSpecimen Inc. has implemented a 1-for-40 reverse stock split to boost its share price and maintain Nasdaq listing compliance.

iSpecimen Inc. announced its 2025 Annual Meeting of Stockholders has been adjourned for the fifth time due to a lack of quorum, with the next reconvened meeting scheduled for May 8, 2026.

iSpecimen Inc. reported a significant 76% revenue decrease for the nine months ended September 30, 2025, alongside a reduced net loss and successful capital raises, but faces ongoing legal challenges and a 'going concern' warning.

iSpecimen Inc. reported a 66% revenue drop and worsening working capital for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite significant cost reductions and recent capital raises.

iSpecimen Inc.'s Q1 2025 revenue decreased by 54% year-over-year, while the company continued to implement cost-cutting measures and address a material weakness in internal controls.

iSpecimen Inc. reported a slight decrease in revenue for Q3 2024, alongside significant reductions in operating expenses and a net loss improvement compared to the same period last year.

iSpecimen Inc. saw a significant increase in revenue during the second quarter of 2024, but ongoing losses and negative working capital raise concerns about the company's ability to continue as a going concern.

iSpecimen Inc. reported a decrease in revenue for the first quarter of 2024, alongside ongoing cost-cutting measures and a focus on new revenue enhancement projects.

iSpecimen Inc. disclosed a 79% revenue drop and continued net losses in its 2025 annual report, alongside significant cost reductions and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.

iSpecimen Inc.'s annual report reveals a net loss of $12.5 million for 2024 and raises substantial doubt about the company's ability to continue as a going concern.

iSpecimen Inc.'s 2023 annual report reveals a net loss of $11.1 million and a material weakness in internal controls, alongside efforts to enhance its marketplace platform and address financial challenges.

Director Avtar Dhaliwal reports the acquisition of stock options in iSpecimen Inc. following a reverse stock split.

Director Richard Paolone acquired stock options in iSpecimen Inc. on September 25, 2024.

Director Katharyn Field reports the acquisition of stock options in iSpecimen Inc. following a 20-for-1 reverse stock split.

Director Andrew L. Ross reports the acquisition of stock options in iSpecimen Inc.

Theresa L. Mock, a director of iSpecimen Inc., reports the acquisition of stock options on January 2, 2024.

Director Elizabeth Ames Graham reports acquisition of 8,340 iSpecimen Inc. stock options on March 21, 2024.

iSpecimen Inc. filed an amendment to its proxy statement to clarify the quorum requirement for its 2025 Annual Meeting, reducing it to 34% of voting power.

iSpecimen Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, and a new 2025 Stock Incentive Plan.

iSpecimen Inc. calls a special meeting to vote on a reverse stock split, authorized share increase, and new financing mechanisms to maintain Nasdaq listing and fund a digital asset treasury.

iSpecimen Inc. is asking stockholders to approve a reverse stock split at its upcoming annual meeting to maintain compliance with Nasdaq's minimum bid price requirement.

iSpecimen Inc. has entered into a consulting agreement with IR Agency LLC and is proceeding with a public offering of its common stock.

iSpecimen Inc. has filed an S-1/A amendment detailing the terms of a proposed offering of common stock and pre-funded warrants.

iSpecimen Inc. has filed a registration statement for a best-efforts offering of up to $4 million in common stock and pre-funded warrants.

iSpecimen Inc. filed an S-1/A to register 1,559,828 shares for resale by selling stockholders, while also detailing its new $200 million Solana blockchain-based corporate treasury reserve initiative and ongoing Nasdaq compliance challenges.

iSpecimen Inc. filed an amended S-1 registration statement, revealing continued net losses, a new Solana-based corporate treasury initiative, and a resale offering of 1.56 million shares by selling stockholders.

iSpecimen Inc. reported a significant revenue decline and continued losses, raising substantial doubt about its ability to continue as a going concern, while also announcing plans for a high-risk Solana blockchain-based corporate treasury.

OBF Investments, LLC and George H. Scholl have reported beneficial ownership of 4.4% of iSpecimen Inc.'s common stock, reflecting holdings after the company's one-for-twenty reverse stock split.